BACKGROUND: Arterial bypass graft implantation remains the primary therapy for patients with advanced cardiovascular disease; however, there is no available synthetic small-diameter vascular graft. METHODS: Tissue-engineered vessels were grown from human smooth muscle cells that were seeded on a biodegradable scaffold using a biomimetic perfusion system. The human tissue-engineered vessels (hTEV) were decellularized by a two-step process using a combination of detergents and hypertonic solutions. The mechanical characteristics were assessed by suture retention strength and burst pressure. The decellularized hTEV were implanted as aortic interpositional grafts in nude rats to evaluate in vivo performance as an arterial graft over a 6-week period. RESULTS: The human tissue-engineered structure formed a vessel composed of smooth muscle cells and the extracellular matrix proteins, including collagen. After decellularization, the collagen matrix remained intact while the cellular components were removed. The mechanical strength of the hTEV after decellularization was similar to human vein in vitro, with a burst pressure of 1,567 ± 384 mm Hg (n = 3) versus 1,680 ± 307 mm Hg for human saphenous vein. The hTEVs had a high patency rate (four of five grafts) without evidence of rupture or aneurysm over a 6-week period as an aortic interpositional graft in a nude rat model. Histologic analysis showed a thin neointima with a confluent endothelium and a subendothelial layer of smooth muscle cells on the explanted tissue-engineered vessels. Transmission electron microscopy on the explanted tissue demonstrated elastin formation in the neointima and intact residual collagen fibers from the tissue-engineered vessel. CONCLUSIONS: The hTEV had a high patency rate and remained mechanically stable as an aortic interpositional graft in a nude rat. The vessel supported the growth of a neointima with endothelial cells and smooth muscle cells. The host remodeling suggested the engineered matrix had a positive effect to create a regenerated vascular graft.
BACKGROUND: Arterial bypass graft implantation remains the primary therapy for patients with advanced cardiovascular disease; however, there is no available synthetic small-diameter vascular graft. METHODS: Tissue-engineered vessels were grown from human smooth muscle cells that were seeded on a biodegradable scaffold using a biomimetic perfusion system. The human tissue-engineered vessels (hTEV) were decellularized by a two-step process using a combination of detergents and hypertonic solutions. The mechanical characteristics were assessed by suture retention strength and burst pressure. The decellularized hTEV were implanted as aortic interpositional grafts in nude rats to evaluate in vivo performance as an arterial graft over a 6-week period. RESULTS: The human tissue-engineered structure formed a vessel composed of smooth muscle cells and the extracellular matrix proteins, including collagen. After decellularization, the collagen matrix remained intact while the cellular components were removed. The mechanical strength of the hTEV after decellularization was similar to human vein in vitro, with a burst pressure of 1,567 ± 384 mm Hg (n = 3) versus 1,680 ± 307 mm Hg for human saphenous vein. The hTEVs had a high patency rate (four of five grafts) without evidence of rupture or aneurysm over a 6-week period as an aortic interpositional graft in a nude rat model. Histologic analysis showed a thin neointima with a confluent endothelium and a subendothelial layer of smooth muscle cells on the explanted tissue-engineered vessels. Transmission electron microscopy on the explanted tissue demonstrated elastin formation in the neointima and intact residual collagen fibers from the tissue-engineered vessel. CONCLUSIONS: The hTEV had a high patency rate and remained mechanically stable as an aortic interpositional graft in a nude rat. The vessel supported the growth of a neointima with endothelial cells and smooth muscle cells. The host remodeling suggested the engineered matrix had a positive effect to create a regenerated vascular graft.
Authors: Rizwan A Manji; Lin F Zhu; Nimrit K Nijjar; David C Rayner; Greg S Korbutt; Thomas A Churchill; Ray V Rajotte; Arvind Koshal; David B Ross Journal: Circulation Date: 2006-07-10 Impact factor: 29.690
Authors: Todd N McAllister; Marcin Maruszewski; Sergio A Garrido; Wojciech Wystrychowski; Nathalie Dusserre; Alicia Marini; Krzysztof Zagalski; Alejandro Fiorillo; Hernan Avila; Ximena Manglano; Jorge Antonelli; Alfred Kocher; Marian Zembala; Lech Cierpka; Luis M de la Fuente; Nicolas L'heureux Journal: Lancet Date: 2009-04-25 Impact factor: 79.321
Authors: Alejandro Nieponice; Lorenzo Soletti; Jianjun Guan; Yi Hong; Burhan Gharaibeh; Timothy M Maul; Johnny Huard; William R Wagner; David A Vorp Journal: Tissue Eng Part A Date: 2010-04 Impact factor: 3.845
Authors: Leigh G Griffiths; Leila H Choe; Kenneth F Reardon; Steven W Dow; E Christopher Orton Journal: Biomaterials Date: 2008-06-02 Impact factor: 12.479
Authors: Elizabeth A Calle; Sam Vesuna; Sashka Dimitrievska; Kevin Zhou; Angela Huang; Liping Zhao; Laura E Niklason; Michael J Levene Journal: Tissue Eng Part C Methods Date: 2014-01-16 Impact factor: 3.056
Authors: Bin Jiang; Rachel Suen; Jiao-Jing Wang; Zheng J Zhang; Jason A Wertheim; Guillermo A Ameer Journal: Adv Healthc Mater Date: 2016-04-24 Impact factor: 9.933
Authors: Daniel von Bornstädt; Hanjay Wang; Michael J Paulsen; Andrew B Goldstone; Anahita Eskandari; Akshara Thakore; Lyndsay Stapleton; Amanda N Steele; Vi N Truong; Kevin Jaatinen; Camille Hironaka; Y Joseph Woo Journal: Circulation Date: 2018-11-06 Impact factor: 29.690
Authors: Liping Zhao; Sumati Sundaram; Andrew V Le; Angela H Huang; Jiasheng Zhang; Go Hatachi; Arkadi Beloiartsev; Michael G Caty; Tai Yi; Katherine Leiby; Ashley Gard; Mehmet H Kural; Liqiong Gui; Kevin A Rocco; Amogh Sivarapatna; Elizabeth Calle; Allison Greaney; Luca Urbani; Panagiotis Maghsoudlou; Alan Burns; Paolo DeCoppi; Laura E Niklason Journal: Tissue Eng Part A Date: 2016-09 Impact factor: 3.845